| 1 | statistics | 2,559 |
| 2 | claims | 1,686 |
| 3 | statistic | 1,189 |
| 4 | payments | 136 |
| 5 | submissions | 131 |
| 6 | reimbursements | 29 |
| 7 | tariffs | 23 |
| 8 | tariff | 21 |
| 9 | dian | 19 |
| 10 | lawsuits | 17 |
| 11 | 2-c | 12 |
| 12 | vfg | 10 |
| 13 | -hcg | 9 |
| 14 | dielectrics | 9 |
| 15 | rebates | 9 |
| 16 | compendia | 7 |
| 17 | mapper | 7 |
| 18 | -medicare | 6 |
| 19 | dosemeter | 6 |
| 20 | pharmacare | 5 |
| 21 | ≥0.90 | 5 |
| 22 | -control | 4 |
| 23 | vespae | 4 |
| 24 | -2010 | 3 |
| 25 | axe | 3 |
| 26 | bootstraps | 3 |
| 27 | o.o | 3 |
| 28 | opioid-receptors | 3 |
| 29 | -medicare-linked | 2 |
| 30 | =2.30 | 2 |
| 31 | cmax/auc | 2 |
| 32 | coefficient=-0.307 | 2 |
| 33 | cohens | 2 |
| 34 | desing | 2 |
| 35 | guided-self-help | 2 |
| 36 | knowledgeln-frastructure | 2 |
| 37 | oritt | 2 |
| 38 | pseudo-values | 2 |
| 39 | pulleys | 2 |
| 40 | result-based | 2 |
| 41 | stabilogram | 2 |
| 42 | transus | 2 |
| 43 | trendline | 2 |
| 44 | www.cochrane.org/ | 2 |
| 45 | -.258 | 1 |
| 46 | -1.508 | 1 |
| 47 | -3.742 | 1 |
| 48 | -australia | 1 |
| 49 | -carboline | 1 |
| 50 | -d-glucopyranosyl-b-sitosterol | 1 |
| 51 | 0.6697 | 1 |
| 52 | 1.3-5.4‰ | 1 |
| 53 | 11.338 | 1 |
| 54 | 11.567 | 1 |
| 55 | 13.7±4.4seconds | 1 |
| 56 | 134.228 | 1 |
| 57 | 2-integrin | 1 |
| 58 | 2-microglobin | 1 |
| 59 | 3-14® | 1 |
| 60 | 4.0/6.8 | 1 |
| 61 | 44-slice | 1 |
| 62 | 9.0/13.0 | 1 |
| 63 | 9.5/10 | 1 |
| 64 | =-0.136 | 1 |
| 65 | =-0.208 | 1 |
| 66 | =-0.354 | 1 |
| 67 | =-2.00 | 1 |
| 68 | =0.203 | 1 |
| 69 | =0.396 | 1 |
| 70 | =2.314 | 1 |
| 71 | =5.786 | 1 |
| 72 | =6.667 | 1 |
| 73 | =8.847 | 1 |
| 74 | advantages/risks | 1 |
| 75 | ampi | 1 |
| 76 | and-tec | 1 |
| 77 | andcolleagues | 1 |
| 78 | anomers | 1 |
| 79 | attributions-as | 1 |
| 80 | australian-dutch | 1 |
| 81 | b-activation | 1 |
| 82 | behrens-fisher | 1 |
| 83 | coefficient=-0.36 | 1 |
| 84 | coefficient=-0.47 | 1 |
| 85 | coefficient=-1.068 | 1 |
| 86 | coefficient=0.035 | 1 |
| 87 | cost-outcome | 1 |
| 88 | cyclotetramethylene | 1 |
| 89 | data.there | 1 |
| 90 | eco-remedy | 1 |
| 91 | estimate=0.14 | 1 |
| 92 | fagerstöma | 1 |
| 93 | hr=0.627 | 1 |
| 94 | hr=0.807 | 1 |
| 95 | hr=0.911 | 1 |
| 96 | hr=0.946 | 1 |
| 97 | hr=0.990 | 1 |
| 98 | interview-12 | 1 |
| 99 | kappabeta | 1 |
| 100 | loathsome | 1 |
| 101 | macro-criteria | 1 |
| 102 | meal+itopride | 1 |
| 103 | miqu | 1 |
| 104 | mnsq | 1 |
| 105 | motion-sensitization | 1 |
| 106 | ocimene | 1 |
| 107 | oleaginesity | 1 |
| 108 | oligomicroarrays | 1 |
| 109 | or=1·24 | 1 |
| 110 | or=1·30 | 1 |
| 111 | or=1·52 | 1 |
| 112 | ordering/results | 1 |
| 113 | organ-support | 1 |
| 114 | pharmacy-benefit | 1 |
| 115 | population=517 | 1 |
| 116 | positive/ | 1 |
| 117 | prescription-claims | 1 |
| 118 | rec/pit | 1 |
| 119 | resources-yielded | 1 |
| 120 | rr=2.034 | 1 |
| 121 | rs1801020 | 1 |
| 122 | scanner-based | 1 |
| 123 | score/month | 1 |
| 124 | scores≥8 | 1 |
| 125 | sequevar | 1 |
| 126 | shotgun-sequencing | 1 |
| 127 | statistics.the | 1 |
| 128 | statpac-2 | 1 |
| 129 | sub-study.practices | 1 |
| 130 | subcriteria | 1 |
| 131 | techinques | 1 |
| 132 | tests/kruskal-wallis | 1 |
| 133 | two-related | 1 |
| 134 | ultrathin-layer | 1 |
| 135 | uni-zap | 1 |
| 136 | value=0.031 | 1 |
| 137 | value=0.053 | 1 |
| 138 | values=1.00 | 1 |
| 139 | voice-dimensions | 1 |
| 140 | within-cow | 1 |
| 141 | yhlén | 1 |
| 142 | z=6.281 | 1 |
| 143 | δ5,8,11,14 | 1 |
| 144 | ≥8/10 | 1 |
| 145 | ≯60 | 1 |
| 1 | -.258 | 1 |
| 2 | -1.508 | 1 |
| 3 | -2010 | 3 |
| 4 | -3.742 | 1 |
| 5 | -australia | 1 |
| 6 | -carboline | 1 |
| 7 | -control | 4 |
| 8 | -d-glucopyranosyl-b-sitosterol | 1 |
| 9 | -hcg | 9 |
| 10 | -medicare | 6 |
| 11 | -medicare-linked | 2 |
| 12 | 0.6697 | 1 |
| 13 | 1.3-5.4‰ | 1 |
| 14 | 11.338 | 1 |
| 15 | 11.567 | 1 |
| 16 | 13.7±4.4seconds | 1 |
| 17 | 134.228 | 1 |
| 18 | 2-c | 12 |
| 19 | 2-integrin | 1 |
| 20 | 2-microglobin | 1 |
| 21 | 3-14® | 1 |
| 22 | 4.0/6.8 | 1 |
| 23 | 44-slice | 1 |
| 24 | 9.0/13.0 | 1 |
| 25 | 9.5/10 | 1 |
| 26 | =-0.136 | 1 |
| 27 | =-0.208 | 1 |
| 28 | =-0.354 | 1 |
| 29 | =-2.00 | 1 |
| 30 | =0.203 | 1 |
| 31 | =0.396 | 1 |
| 32 | =2.30 | 2 |
| 33 | =2.314 | 1 |
| 34 | =5.786 | 1 |
| 35 | =6.667 | 1 |
| 36 | =8.847 | 1 |
| 37 | advantages/risks | 1 |
| 38 | ampi | 1 |
| 39 | and-tec | 1 |
| 40 | andcolleagues | 1 |
| 41 | anomers | 1 |
| 42 | attributions-as | 1 |
| 43 | australian-dutch | 1 |
| 44 | axe | 3 |
| 45 | b-activation | 1 |
| 46 | behrens-fisher | 1 |
| 47 | bootstraps | 3 |
| 48 | claims | 1,686 |
| 49 | cmax/auc | 2 |
| 50 | coefficient=-0.307 | 2 |
| 51 | coefficient=-0.36 | 1 |
| 52 | coefficient=-0.47 | 1 |
| 53 | coefficient=-1.068 | 1 |
| 54 | coefficient=0.035 | 1 |
| 55 | cohens | 2 |
| 56 | compendia | 7 |
| 57 | cost-outcome | 1 |
| 58 | cyclotetramethylene | 1 |
| 59 | data.there | 1 |
| 60 | desing | 2 |
| 61 | dian | 19 |
| 62 | dielectrics | 9 |
| 63 | dosemeter | 6 |
| 64 | eco-remedy | 1 |
| 65 | estimate=0.14 | 1 |
| 66 | fagerstöma | 1 |
| 67 | guided-self-help | 2 |
| 68 | hr=0.627 | 1 |
| 69 | hr=0.807 | 1 |
| 70 | hr=0.911 | 1 |
| 71 | hr=0.946 | 1 |
| 72 | hr=0.990 | 1 |
| 73 | interview-12 | 1 |
| 74 | kappabeta | 1 |
| 75 | knowledgeln-frastructure | 2 |
| 76 | lawsuits | 17 |
| 77 | loathsome | 1 |
| 78 | macro-criteria | 1 |
| 79 | mapper | 7 |
| 80 | meal+itopride | 1 |
| 81 | miqu | 1 |
| 82 | mnsq | 1 |
| 83 | motion-sensitization | 1 |
| 84 | o.o | 3 |
| 85 | ocimene | 1 |
| 86 | oleaginesity | 1 |
| 87 | oligomicroarrays | 1 |
| 88 | opioid-receptors | 3 |
| 89 | or=1·24 | 1 |
| 90 | or=1·30 | 1 |
| 91 | or=1·52 | 1 |
| 92 | ordering/results | 1 |
| 93 | organ-support | 1 |
| 94 | oritt | 2 |
| 95 | payments | 136 |
| 96 | pharmacare | 5 |
| 97 | pharmacy-benefit | 1 |
| 98 | population=517 | 1 |
| 99 | positive/ | 1 |
| 100 | prescription-claims | 1 |
| 101 | pseudo-values | 2 |
| 102 | pulleys | 2 |
| 103 | rebates | 9 |
| 104 | rec/pit | 1 |
| 105 | reimbursements | 29 |
| 106 | resources-yielded | 1 |
| 107 | result-based | 2 |
| 108 | rr=2.034 | 1 |
| 109 | rs1801020 | 1 |
| 110 | scanner-based | 1 |
| 111 | score/month | 1 |
| 112 | scores≥8 | 1 |
| 113 | sequevar | 1 |
| 114 | shotgun-sequencing | 1 |
| 115 | stabilogram | 2 |
| 116 | statistic | 1,189 |
| 117 | statistics | 2,559 |
| 118 | statistics.the | 1 |
| 119 | statpac-2 | 1 |
| 120 | sub-study.practices | 1 |
| 121 | subcriteria | 1 |
| 122 | submissions | 131 |
| 123 | tariff | 21 |
| 124 | tariffs | 23 |
| 125 | techinques | 1 |
| 126 | tests/kruskal-wallis | 1 |
| 127 | transus | 2 |
| 128 | trendline | 2 |
| 129 | two-related | 1 |
| 130 | ultrathin-layer | 1 |
| 131 | uni-zap | 1 |
| 132 | value=0.031 | 1 |
| 133 | value=0.053 | 1 |
| 134 | values=1.00 | 1 |
| 135 | vespae | 4 |
| 136 | vfg | 10 |
| 137 | voice-dimensions | 1 |
| 138 | within-cow | 1 |
| 139 | www.cochrane.org/ | 2 |
| 140 | yhlén | 1 |
| 141 | z=6.281 | 1 |
| 142 | δ5,8,11,14 | 1 |
| 143 | ≥0.90 | 5 |
| 144 | ≥8/10 | 1 |
| 145 | ≯60 | 1 |
| 1 | positive/ | 1 |
| 2 | www.cochrane.org/ | 2 |
| 3 | 9.0/13.0 | 1 |
| 4 | values=1.00 | 1 |
| 5 | =-2.00 | 1 |
| 6 | 9.5/10 | 1 |
| 7 | ≥8/10 | 1 |
| 8 | -2010 | 3 |
| 9 | rs1801020 | 1 |
| 10 | =2.30 | 2 |
| 11 | or=1·30 | 1 |
| 12 | ≯60 | 1 |
| 13 | ≥0.90 | 5 |
| 14 | hr=0.990 | 1 |
| 15 | hr=0.911 | 1 |
| 16 | value=0.031 | 1 |
| 17 | z=6.281 | 1 |
| 18 | statpac-2 | 1 |
| 19 | interview-12 | 1 |
| 20 | -3.742 | 1 |
| 21 | or=1·52 | 1 |
| 22 | =0.203 | 1 |
| 23 | value=0.053 | 1 |
| 24 | δ5,8,11,14 | 1 |
| 25 | estimate=0.14 | 1 |
| 26 | =2.314 | 1 |
| 27 | or=1·24 | 1 |
| 28 | rr=2.034 | 1 |
| 29 | =-0.354 | 1 |
| 30 | coefficient=0.035 | 1 |
| 31 | coefficient=-0.36 | 1 |
| 32 | =-0.136 | 1 |
| 33 | hr=0.946 | 1 |
| 34 | =5.786 | 1 |
| 35 | =0.396 | 1 |
| 36 | coefficient=-0.307 | 2 |
| 37 | hr=0.807 | 1 |
| 38 | population=517 | 1 |
| 39 | hr=0.627 | 1 |
| 40 | coefficient=-0.47 | 1 |
| 41 | =8.847 | 1 |
| 42 | 11.567 | 1 |
| 43 | =6.667 | 1 |
| 44 | 0.6697 | 1 |
| 45 | 4.0/6.8 | 1 |
| 46 | =-0.208 | 1 |
| 47 | -1.508 | 1 |
| 48 | 134.228 | 1 |
| 49 | 11.338 | 1 |
| 50 | -.258 | 1 |
| 51 | coefficient=-1.068 | 1 |
| 52 | scores≥8 | 1 |
| 53 | compendia | 7 |
| 54 | -australia | 1 |
| 55 | macro-criteria | 1 |
| 56 | subcriteria | 1 |
| 57 | fagerstöma | 1 |
| 58 | kappabeta | 1 |
| 59 | 2-c | 12 |
| 60 | and-tec | 1 |
| 61 | statistic | 1,189 |
| 62 | cmax/auc | 2 |
| 63 | resources-yielded | 1 |
| 64 | -medicare-linked | 2 |
| 65 | scanner-based | 1 |
| 66 | result-based | 2 |
| 67 | two-related | 1 |
| 68 | vespae | 4 |
| 69 | 44-slice | 1 |
| 70 | meal+itopride | 1 |
| 71 | statistics.the | 1 |
| 72 | cost-outcome | 1 |
| 73 | loathsome | 1 |
| 74 | cyclotetramethylene | 1 |
| 75 | ocimene | 1 |
| 76 | trendline | 2 |
| 77 | -carboline | 1 |
| 78 | pharmacare | 5 |
| 79 | -medicare | 6 |
| 80 | data.there | 1 |
| 81 | knowledgeln-frastructure | 2 |
| 82 | axe | 3 |
| 83 | tariff | 21 |
| 84 | -hcg | 9 |
| 85 | vfg | 10 |
| 86 | shotgun-sequencing | 1 |
| 87 | desing | 2 |
| 88 | australian-dutch | 1 |
| 89 | score/month | 1 |
| 90 | ampi | 1 |
| 91 | -d-glucopyranosyl-b-sitosterol | 1 |
| 92 | -control | 4 |
| 93 | stabilogram | 2 |
| 94 | dian | 19 |
| 95 | 2-microglobin | 1 |
| 96 | 2-integrin | 1 |
| 97 | b-activation | 1 |
| 98 | motion-sensitization | 1 |
| 99 | yhlén | 1 |
| 100 | o.o | 3 |
| 101 | uni-zap | 1 |
| 102 | guided-self-help | 2 |
| 103 | mnsq | 1 |
| 104 | sequevar | 1 |
| 105 | behrens-fisher | 1 |
| 106 | mapper | 7 |
| 107 | dosemeter | 6 |
| 108 | ultrathin-layer | 1 |
| 109 | attributions-as | 1 |
| 110 | dielectrics | 9 |
| 111 | statistics | 2,559 |
| 112 | 13.7±4.4seconds | 1 |
| 113 | sub-study.practices | 1 |
| 114 | rebates | 9 |
| 115 | andcolleagues | 1 |
| 116 | pseudo-values | 2 |
| 117 | techinques | 1 |
| 118 | tariffs | 23 |
| 119 | tests/kruskal-wallis | 1 |
| 120 | advantages/risks | 1 |
| 121 | claims | 1,686 |
| 122 | prescription-claims | 1 |
| 123 | cohens | 2 |
| 124 | voice-dimensions | 1 |
| 125 | submissions | 131 |
| 126 | bootstraps | 3 |
| 127 | anomers | 1 |
| 128 | opioid-receptors | 3 |
| 129 | lawsuits | 17 |
| 130 | ordering/results | 1 |
| 131 | reimbursements | 29 |
| 132 | payments | 136 |
| 133 | transus | 2 |
| 134 | oligomicroarrays | 1 |
| 135 | pulleys | 2 |
| 136 | pharmacy-benefit | 1 |
| 137 | rec/pit | 1 |
| 138 | organ-support | 1 |
| 139 | oritt | 2 |
| 140 | miqu | 1 |
| 141 | within-cow | 1 |
| 142 | eco-remedy | 1 |
| 143 | oleaginesity | 1 |
| 144 | 3-14® | 1 |
| 145 | 1.3-5.4‰ | 1 |